Business context and reporting period
This is Celsion Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015, filed August 10, 2015. The request identifies Imunon, Inc., but the filing is for Celsion Corporation; the filing text does not explain this company-name discrepancy.
Celsion was a clinical-stage oncology drug developer. Its lead candidate, ThermoDox, was in Phase III development for primary liver cancer and Phase II development for recurrent chest-wall breast cancer. Its pipeline also included GEN-1 and acquired EGEN nucleic-acid therapy platforms. The company reported no meaningful product-sales revenue.
Financial results and liquidity
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $125,000 | $125,000 | $250,000 | $250,000 |
| Operating expenses | $5.37 million | $6.54 million | $11.91 million | $11.86 million |
| Operating loss | $5.24 million | $6.41 million | $11.66 million | $11.61 million |
| Net loss | $5.67 million | $6.67 million | $12.68 million | $12.10 million |
| Loss per share, basic and diluted | $0.27 | $0.38 | $0.62 | $0.71 |
- Revenue was licensing revenue recognized from a $5 million Hisun technology-development payment, amortized over the agreement term. No product revenue was reported.
- For the first six months, research and development expense rose 33% to $8.07 million, principally reflecting the integrated EGEN operations and increased clinical research spending. General and administrative expense fell 19% to $3.83 million; prior-year acquisition costs were $1.07 million.
- Cash and cash equivalents were $11.95 million; available-for-sale investments were $18.78 million, with $52,000 accrued interest receivable. Combined cash and investments plus related interest were approximately $30.8 million.
- First-half operating cash use was $11.61 million, compared with $9.01 million in 2014. Financing provided $5.47 million, including $7.25 million net equity proceeds, partly offset by $1.78 million in debt principal payments.
- Working capital was $21.7 million, down from $27.4 million at December 31, 2014. Total liabilities were $31.31 million; stockholders’ equity was $29.11 million.
- Notes payable had a $3.87 million current portion and $4.29 million non-current portion; scheduled principal before debt discount totaled $8.22 million. The Hercules debt carried an 11.25% prime-based rate and was secured. The company said it was compliant with its covenants.
- The EGEN earn-out milestone liability was $13.91 million, a Level 3 fair-value estimate; the maximum potential future payments were $30.4 million. The company recorded a $241,528 non-cash first-half charge from revaluation.
Material changes versus the prior comparable period
- Second-quarter net loss narrowed by about $1.0 million, as lower total operating expenses outweighed higher interest and other expenses. First-half net loss increased by about $584,000 year over year.
- First-half operating cash use increased by about $2.6 million year over year. Cash and investments including related interest fell from $37.1 million at year-end 2014 to $30.8 million at June 30, 2015.
- On June 1, 2015, Celsion issued 3.0 million shares at $2.675 per share, raising $8.0 million gross, and issued five-year warrants for up to 1.95 million shares at $2.60. The filing reports net proceeds of $7.25 million for the first half.
- In Q2 2015, the Hercules warrant’s price-adjustment provision expired; its $336,254 liability was reclassified to equity after fair-value adjustments. The related warrant liability was zero at June 30.
Outlook, commentary, and risks
- Management estimated that June 30 cash and investment resources would fund operations into the first half of 2017. It also stated that substantial additional capital would be needed to develop candidates, obtain approvals, and commercialize any approved products; no committed financing source was identified.
- Management expected significant operating losses to continue. If financing is unavailable on acceptable terms, the company said it might delay, reduce, or terminate programs, restructure operations, or relinquish technology or product rights. Further equity financing could materially dilute shareholders.
- The Phase III HEAT study of ThermoDox with radiofrequency ablation had failed its primary progression-free-survival endpoint. Management cited a favorable post-hoc overall-survival subgroup analysis, but those findings were not confirmatory evidence; the new Phase III OPTIMA study was designed around optimized ablation and overall survival.
- Management reported positive interim DIGNITY results: 13 patients were evaluable, with a 69% local response rate, and expected enrollment completion in Q3 2015. These were interim results from a small trial, not established efficacy.
- Management planned to begin a Phase I GEN-1 ovarian cancer trial in the second half of 2015. A separate GEN-1 combination trial in platinum-resistant ovarian cancer was expected to begin enrollment in the first half of 2016.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, dependence on third-party manufacturers and clinical research organizations, competition, intellectual-property and licensing risks, integration of EGEN, ongoing losses, capital needs and potential share dilution. The filing reported no legal proceedings and no off-balance-sheet financing arrangements.
Important facts for investors to verify
- Confirm the issuer identity: this filing is Celsion Corporation’s, not Imunon, Inc.’s.
- Review subsequent OPTIMA enrollment, trial design and outcome disclosures, and distinguish confirmatory trial results from the HEAT post-hoc subgroup analysis.
- Track actual cash burn, financing needs and runway against management’s estimate into the first half of 2017.
- Assess dilution from the 2015 offering, its warrants, outstanding equity awards, and any further financing.
- Monitor Hercules debt service and the contingent EGEN earn-out, including the potential maximum payments and fair-value assumptions.
- Check whether the reported DIGNITY and GEN-1 timelines and interim findings were borne out in later filings.